Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Syringin, also known as Eleutheroside B, is a naturally occurring phenolic glycoside and a major bioactive component found in plants such as *Acanthopanax senticosus* (Siberian ginseng), *Syringa oblata*, and *Fraxinus rhynchophylla*. As a small molecule natural product, it is primarily utilized as a research compound and a marker for the quality control of traditional Chinese medicine (TCM) preparations like Aidi injection, Compound cantharidin capsule, and Tanreqing injection. Syringin has demonstrated a wide range of pharmacological activities in preclinical studies, including immunomodulatory, anti-inflammatory, anti-tumor, antihyperglycemic, and neuroprotective effects. Its mechanism of action involves the modulation of several signaling pathways, including the inhibition of NF-κB and PI3K/AKT, and potential interaction with targets such as TGF-βR1, EGFR, and COX-2. While it is widely studied for its potential in treating metabolic disorders, cancer, and inflammation, it is not currently an approved pharmaceutical drug developed by a specific company as a novel therapeutic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on syringin.